Rarebase, a platform drug development biotechnology company, has appointed Chris Moxham, President. In addition to continuing to serve as chief scientific officer, Moxham will be responsible for driving the company’s strategic plan for growth. Moxham’s career spans more than 25 years in drug discovery focused on cutting-edge science and drug hunting in large pharma and biotech. He spent two decades at Eli Lilly and Co. where he helped bring over 10 molecules into the clinic across multiple th...